@FierceMedDev: Echo Therapeutics finds a China partner for its glucose monitor, satisfies an angry investor. Article | Follow @FierceMedDev
@MarkHFierce: Presenting, our latest issue of FierceDiagnostics--check it out, and tell a friend. Issue | Follow @MarkHFierce
@MichaelGFierce: Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. More from FierceDrugDelivery | Follow @MichaelGFierce
@GalenMoore: Imploding microbubbles give transdermal patch an edge over arthritis. Story | Follow @GalenMoore
> Johnson & Johnson's ($JNJ) Ethicon Endo-Surgery arm won 510(k) clearance for a next-generation ultrasonic surgical shear device. Item
> W.L. Gore won FDA approval to expand the use of its Viabahn Endoprosthesis device to treat hemodialysis patients. Item
> Analogic lost money in its fiscal 2014 first quarter due, in part, to a major drop in medical imaging sales. Item
> Spain's Venter Pharma licensed NovaMedica the rights to market a new diagnostic test for lactose intolerance in Russia. Item
> The market for antimicrobial coatings--which affects medical devices and many other industries--will be worth nearly $3 billion by 2018, according to a new market report. Item
Biotech News
@FierceBiotech: Big Biopharmas help fuel $26M round for Sutro's antibody R&D work. News | Follow @FierceBiotech
@JohnCFierce: GEN ranks VCs by total funds under management. Hmmmm. Feature via GEN | Follow @JohnCFierce
@DamianFierce: With fresh hopes and a bunch of new safety data, Orexigen is going back to the FDA with Contrave. Story | Follow @DamianFierce
@EmilyMFierce: 1 in 100 cancers are associated with a particular gene mutation, according to a Sanger Institute study. Story from FierceBiotech Research | Follow @EmilyMFierce
> Avanir hits the skids after its pain drug flunks a mid-stage study. More
> Celgene chips in $20M to extend Agios cancer deal. Story
Pharma News
@FiercePharma: Tuesday's best-read new news: Teva braces for $550M hit from Copaxone generics. Story | Follow @FiercePharma
@EricPFierce: The here and now of track and trace. Editor's corner | Follow @EricPFierce
@CarlyHFierce: Tuesday's most popular special report: Top 10 generics makers by 2012 revenue. Report | Follow @CarlyHFierce
> GlaxoSmithKline pledges $330M to ramp up Relvar production, expand in U.K. Story
> Vice president clears way for FDA to add inspectors in China. Article
> Pricey hep C drugs, beware: Express Scripts plans a showdown. More
Diagnostics News
> French company unveils prenatal test based on licensed Sequenom tech. Story
> DioGenix's venture round fuels expanded trial for MS molecular Dx test. Report
> New Hologic CEO pledges to grow, and not sell, the women's health Dx company. More
> Foundation Medicine shows test's worth as a highly specific blood cancer screening tool. Article
> Invitae's $40M Series E adds rocket fuel to genetic test expansion plans. News
> Sequenta expands reach of ultrasensitive cancer Dx test. Item
Biomarkers News
> Biomarker points to aggressive breast cancer in black women. Story
> Cellular switch biomarker predicts prostate cancer's spread. Piece
> In China, lung cancer biomarker testing is on the rise. More
> Gene biomarker may determine whether some depression drugs will work. News
> New tech promises to speed up biomarker validation. Article
> Inflammatory marker presents a new target for obesity drug developers. Item
Drug Delivery News
> Alliqua CEO: Celgene deal vaults us to 'another level of respectability'. Article
> Protein 'crossing guard' carries Alzheimer's drug past the blood-brain barrier. More
> Imploding microbubbles give transdermal patch an edge for arthritis drugs. News
> Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. Report
> Rutgers team delivers RNA to weaken drug-resistant ovarian cancer. Story
> Swedish team: Omega-3 fatty acids cross blood-brain barrier for possible Alzheimer's treatment. Item